Literature DB >> 1929682

Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation.

M Kutner1, G Nixon, F Silverstone.   

Abstract

The use of oral anticoagulants and antiplatelet agents for the prevention of strokes in elderly patients with atrial fibrillation is controversial. Recent studies suggest that warfarin and aspirin can be safe and effective in selected patients. To determine attitudes toward this subject, we sent a questionnaire to 480 attending physicians at two major university-affiliated medical centers. Among the 251 responses (52.3%), 46 respondents (18.3%) used warfarin in atrial fibrillation of any cause, 175 (69.7%) used it in atrial fibrillation with transient ischemic attacks, 161 (64.1%) used it in patients with cerebrovascular accidents, and 196 (78.0%) used it in patients with mitral valve disease. One hundred twenty-nine (51.4%) believed that the risk of hemorrhage associated with warfarin outweighs the benefit, 61 (24.3%) were not convinced that warfarin prevents strokes in atrial fibrillation, and 42 (16.7%) believed it was difficult to monitor prothrombin time in the elderly because of poor compliance. Aspirin was used by 91 physicians (36.2%) in atrial fibrillation of any cause, 161 (64.1%) in patients with transient ischemic attacks, 140 (55.7%) in patients with cerebrovascular accidents, and 48 (19.1%) when patients were in sinus rhythm. We concluded that physicians are still hesitant to use oral anticoagulants and antiplatelet agents for the prevention of strokes in their elderly patients with atrial fibrillation. These agents are used most frequently after an ischemic episode (transient ischemic attack or cerebrovascular accident) has occurred or in patients with mitral valve disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929682

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  35 in total

Review 1.  Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use.

Authors:  D McCormick; J H Gurwitz; R J Goldberg; J Ansell
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Anticoagulation Management as a Risk Factor for Adverse Events: Grounds for Improvement.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-01       Impact factor: 2.300

3.  Development of a decision aid for atrial fibrillation who are considering antithrombotic therapy.

Authors:  M Man-Son-Hing; A Laupacis; A M O'Connor; R G Hart; G Feldman; J L Blackshear; D C Anderson
Journal:  J Gen Intern Med       Date:  2000-10       Impact factor: 5.128

4.  Physician attitudes concerning anticoagulation services in the long-term care setting.

Authors:  Leslie R Harrold; Jerry H Gurwitz; Janet P Tate; Richard Becker; Tammy Stuart; Anne Elwell; Martha Radford
Journal:  J Thromb Thrombolysis       Date:  2002-08       Impact factor: 2.300

5.  Safety of anticoagulation in the elderly: reasons for discontinuing therapy.

Authors:  P A O'Neill; D Crossley; D A Taberner; D S Fairweather
Journal:  Postgrad Med J       Date:  1992-10       Impact factor: 2.401

6.  The effect of cognitive impairment in the elderly on the initial and long-term stability of warfarin therapy.

Authors:  Hanan S Khreizat; Peter Whittaker; Kristy D Curtis; Gerald Turlo; Candice L Garwood
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

7.  Should we just let the anticoagulation service do it? The conundrum of anticoagulation for atrial fibrillation.

Authors:  D B Matchar; G P Samsa; S J Cohen
Journal:  J Gen Intern Med       Date:  1996-12       Impact factor: 5.128

8.  Atrial fibrillation and stroke: what we know, what's new, and what we should do now.

Authors:  C S Landefeld
Journal:  CMAJ       Date:  1997-09-15       Impact factor: 8.262

9.  Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation.

Authors:  M R Antani; R J Beyth; K E Covinsky; P A Anderson; D G Miller; R D Cebul; L M Quinn; C S Landefeld
Journal:  J Gen Intern Med       Date:  1996-12       Impact factor: 5.128

10.  Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation?

Authors:  R J Beyth; M R Antani; K E Covinsky; D G Miller; M M Chren; L M Quinn; C S Landefeld
Journal:  J Gen Intern Med       Date:  1996-12       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.